Subtype
Male Reproductive System Carcinoma
CI-CAN-00003134Explore in graph →
452 active trials16 approved drugs20 evidence items
- NCIt
- C181196
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003134Explore in graph →
Clinical trials
1,218 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (190)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07164027 | Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial | recruiting | Early Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT05396872 | Patient Decision-making About Precision Oncology in Veterans With Advanced Prostate Cancer | recruiting | N/A | 250 | University of California, San FranciscoOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT06330805 | Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer | recruiting | Phase 2 | 70 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT04943536 | Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer(BiolenRT) | active not recruiting | Phase 1 | 20 | Alessa Therapeutics Inc.INDUSTRY | 1 | Feb 27, 2026 | clinicaltrials |
| NCT02296229 | Stereotactic Body Radiation Therapy in Treating Patients With Localized High-Risk Prostate Cancer | active not recruiting | N/A | 220 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT03016741 | Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer | active not recruiting | Phase 4 | 100 | Northwestern UniversityOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT06650579 | REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial | recruiting | Phase 3 | 72 | Emory UniversityOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT06037863 | Evaluation of the Impact of Empty Versus Full Bladder in Patients With Prostate Cancer, RELIEF Trial | active not recruiting | N/A | 168 | Mayo ClinicOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT07285057 | Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance | recruiting | Phase 2 | 120 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT05720130 | Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study). | recruiting | Phase 1 / Phase 2 | 100 | AdvanCell Pty LimitedINDUSTRY | 1 | Feb 20, 2026 | clinicaltrials |
| NCT07423117 | A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy | not yet recruiting | Phase 1 | 102 | IntoCell, IncINDUSTRY | 0 | Feb 20, 2026 | clinicaltrials |
| NCT07339267 | A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer | recruiting | Phase 1 | 12 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07407959 | Screening and Staging of Benign vs Malignant Pelvic Abnormalities | recruiting | — | 60 | Mayo ClinicOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT05683964 | Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression | active not recruiting | Early Phase 1 | 9 | Beth Israel Deaconess Medical CenterOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT04754191 | Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer(ENCORE) | active not recruiting | Phase 2 | 34 | University of UtahOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT05160597 | Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy | active not recruiting | Early Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT05320406 | RElugolix VErsus LeUprolide Cardiac Trial(REVELUTION) | active not recruiting | Phase 2 | 94 | Emory UniversityOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT04704505 | Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)(BAT-RAD) | recruiting | Phase 2 | 47 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 2 | Feb 6, 2026 | clinicaltrials |
| NCT03260023 | Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers | active not recruiting | Phase 1 / Phase 2 | 143 | TransgeneINDUSTRY | 3 | Feb 5, 2026 | clinicaltrials |
| NCT03902951 | Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer | active not recruiting | Phase 2 | 28 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT04455750 | A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy(CASPAR) | active not recruiting | Phase 3 | 61 | Alliance for Clinical Trials in OncologyOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07276438 | Image-Guidance and Online Adaptation With Stereotactic Body Radiation Therapy for the Treatment of Localized Prostate Cancer, MANTICORE Trial | recruiting | N/A | 186 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT04729114 | A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer | recruiting | Phase 1 | 174 | Astellas Pharma Global Development, Inc.INDUSTRY | 2 | Feb 4, 2026 | clinicaltrials |
| NCT06200974 | Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer(BrachyTRACKS) | recruiting | — | 100 | British Columbia Cancer AgencyOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT05806515 | Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation | recruiting | Phase 2 | 44 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 29, 2026 | clinicaltrials |
| NCT06099093 | Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan | recruiting | Phase 4 | 30 | Brigham and Women's HospitalOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT04734730 | Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer | recruiting | Phase 2 | 70 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06636123 | GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy | recruiting | Phase 1 | 30 | Virginia Commonwealth UniversityOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07291414 | A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients | recruiting | N/A | 80 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT03367702 | Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer | active not recruiting | Phase 3 | 692 | NRG OncologyOTHER | 6 | Jan 15, 2026 | clinicaltrials |
| NCT06830850 | A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer | recruiting | Phase 1 | 25 | Atridia Pty Ltd.INDUSTRY | 1 | Jan 15, 2026 | clinicaltrials |
| NCT05924672 | Efficacy of Ra-223 in PSMA PET Optimally Selected Patients | active not recruiting | Phase 2 | 2 | University of California, San FranciscoOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT06334432 | Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 466 | Nuvation Bio Inc.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT04647526 | Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment(SPLASH) | active not recruiting | Phase 3 | 455 | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and CompanyINDUSTRY | 6 | Jan 13, 2026 | clinicaltrials |
| NCT04686682 | A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors | recruiting | Phase 1 / Phase 2 | 152 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT04777071 | An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer | active not recruiting | Phase 2 | 141 | University of WashingtonOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT05570994 | 177Lu-HTK03170 in mCRPC With PSMA Positive Disease | enrolling by invitation | Phase 1 / Phase 2 | 50 | British Columbia Cancer AgencyOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT06866938 | Study of Re-treatment With [177Lu]Lu-PSMA in Men With Metastatic Castration Resistance Prostate Cancer(ReaLuP) | recruiting | Phase 2 | 58 | Hospices Civils de LyonOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT04763980 | Community-Based Health Coach for Access to Germline Genetic Testing Among African American Men With Prostate Cancer | recruiting | N/A | 72 | University of California, San FranciscoOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT06531499 | A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study(RADIODOSE) | recruiting | Phase 1 | 106 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 31, 2025 | clinicaltrials |
| NCT07310355 | 68Ga-PSMA-0057 and 177Lu-PSMA-0057 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer | not yet recruiting | Phase 1 / Phase 2 | 49 | Chengdu StarRay Therapeutics Co., LtdINDUSTRY | 0 | Dec 30, 2025 | clinicaltrials |
| NCT05519878 | Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers | recruiting | N/A | 224 | City of Hope Medical CenterOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT07302763 | Four-Timepoint Multi-tracer PET Imaging to Characterize Metastatic prOstate Cancer Heterogeneity(4TMPO) | recruiting | N/A | 45 | Frederic PouliotOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT06822491 | Early Magnetic Resonance Imaging Response of the Dominant Intraprostatic Lesion After Online Adaptive Stereotactic Body Radiotherapy for Localized Prostate Cancer and Correlation With Prostate Specific Antigen Response(PRODART) | active not recruiting | — | 28 | University of ZurichOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT06155084 | A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients | recruiting | Phase 1 / Phase 2 | 84 | Hinova Pharmaceuticals Inc.INDUSTRY | 1 | Dec 22, 2025 | clinicaltrials |
| NCT06229366 | [Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer(ACCEL) | active not recruiting | Phase 1 | 142 | Eli Lilly and CompanyINDUSTRY | 1 | Dec 22, 2025 | clinicaltrials |
| NCT04446117 | Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC(CONTACT-02) | active not recruiting | Phase 3 | 575 | ExelixisINDUSTRY | 27 | Dec 18, 2025 | clinicaltrials |
| NCT05998278 | Personalized Optimization of Systematic Prostate Biopsy | recruiting | N/A | 330 | Fujian Medical University Union HospitalOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT06200259 | Reduction of Gastrointestinal Toxicity in Prostate Cancer by Proton Spot Placement | recruiting | N/A | 500 | Covenant Health Cancer CenterOTHER | 1 | Dec 18, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Mar 10, 2026source: clinicaltrials